Antibodies | Targeted Therapy for Antihistamine-Refractory Chronic Spontaneous Urticaria: An Evidence-Graded Approach to Agent Selection

This study provides a critical pathway for precision subtyping treatment of chronic spontaneous urticaria, particularly for patients with low IgE levels or prominent autoimmune features. It clarifies the clinical decision logic for transitioning from anti-IgE therapy to BTK inhibitors or KIT receptor blockers.

 

Literature Overview

The article titled "Targeted Therapy for Antihistamine-Refractory Chronic Spontaneous Urticaria: A Critical Narrative Review and an Evidence-Graded Approach to Agent Selection," published in the journal Antibodies, systematically explores new strategies for selecting targeted therapies based on pathogenic mechanisms and patient characteristics after the failure of second-generation H1 antihistamines. The article reviews the latest clinical evidence for novel therapies ranging from omalizumab to dupilumab, remibrutinib, and bazarolimab, and proposes an evidence-graded, individualized drug selection process.

Background Knowledge

This study aims to address the critical challenge that approximately 30%-50% of patients with chronic spontaneous urticaria do not respond to antihistamines. While blocking IgE-mediated pathways (e.g., omalizumab) remains a first-line choice, its efficacy is limited in patients with autoimmune features (Type IIb). As a downstream signaling molecule, BTK kinase inhibitors can bypass IgE to directly block mast cell activation, whereas KIT receptor blockers function by depleting mast cells themselves. The study focuses on how to precisely sequence various targeted drugs with distinct mechanisms based on patient endotypes (e.g., Type I vs. Type IIb), total IgE levels, basophil functional status, and comorbidities (such as atopic dermatitis), thereby filling the gap in current guidelines regarding second-line treatment options.

 

 

Research Methods and Experiments

This article employs a critical narrative review methodology, searching the PubMed and ClinicalTrials.gov databases to focus on Phase III clinical trial data for omalizumab, dupilumab, remibrutinib, and bazarolimab (e.g., the ASTERIA, CUPID, REMIX, and EMBARQ series of studies). Rather than conducting a systematic review, the authors constructed a predefined evidence grading system (ranging from guidelines to expert opinion) to annotate each clinical claim with its corresponding evidence level. Key evidence supports the biological rationale for different drugs in specific endotype patients, such as the advantage of BTK inhibitors in patients with low IgE levels and the unique mechanism of KIT antibodies in depleting mast cells.

Key Conclusions and Perspectives

• Omalizumab remains the preferred first-line biologic for most patients refractory to antihistamines, but responses in Type IIb autoimmune patients may be delayed or incomplete.
• For patients who fail omalizumab therapy, dupilumab is a rational choice if Type 2 inflammatory features such as atopic dermatitis or asthma are present; conversely, if the patient presents with low total IgE or basopenia, remibrutinib as a BTK inhibitor offers stronger mechanistic alignment.
• Bazarolimab, which directly depletes mast cells by targeting the KIT receptor, has shown significant efficacy in Phase II studies for patients refractory to omalizumab, representing a highly promising future therapeutic direction, although it remains in the experimental stage.
• The selection between BTK inhibitors and anti-KIT therapies requires a risk-benefit analysis: the former necessitates monitoring for bleeding risks, while the latter requires surveillance for neutropenia and changes in pigmentation.

Research Significance and Prospects

From a research perspective, these findings drive a shift in drug development from single-target approaches to multi-mechanism combination or sequential therapies, emphasizing the value of biomarkers (such as total IgE and anti-thyroid peroxidase antibodies) in guiding clinical monitoring. Future research should focus on validating endotype-based stratified treatment strategies and exploring whether mast cell depletion can induce disease-modifying effects (i.e., long-term remission after discontinuation), which would fundamentally transform the treatment paradigm for chronic spontaneous urticaria.

 

 

Conclusion

By deeply analyzing the complex pathogenic mechanisms of chronic spontaneous urticaria, this article establishes a critical pathway for transitioning from empirical treatment to precision medicine. The study indicates that relying solely on anti-IgE strategies is insufficient to meet the needs of all refractory patients; instead, it is essential to flexibly select novel targeted drugs acting on the BTK pathway or KIT receptors based on patient endotype characteristics and comorbidities. This strategy not only improves treatment response rates but also provides a theoretical foundation for the future development of disease-modifying therapies targeting mast cell survival mechanisms. For clinicians, establishing an individualized drug selection process based on biomarkers will be central to improving the quality of life for patients with chronic spontaneous urticaria and achieving long-term disease control.

 

Luca Guarino, Giuseppe Rizzuto, Vincenzo Coppolelli, Steven Nisticò, and Camilla Chello. Targeted Therapy for Antihistamine-Refractory Chronic Spontaneous Urticaria: A Critical Narrative Review and an Evidence-Graded Approach to Agent Selection. Antibodies.